Robert W. Baird analyst Colleen M. Kusy maintained a Buy rating on AVEO Pharma (AVEO – Research Report) on May 5 and set a price target of $17.00. The company's shares closed last Friday at $4.31. According to TipRanks.com, Kusy is ranked 0 out of 5 stars with an average return of -41.6% and a 10.7% success rate. Kusy covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Iovance Biotherapeutics, and Apellis Pharmaceuticals. AVEO Pharma has an analyst consensus of Strong Buy, with a price target consensus of $15.75, implying a 246.2% upside from current levels. In a report released yesterday, H.C.
https://www.tipranks.com/news/blurbs/robert-w-baird-reaffirms-their-buy-rating-on-aveo-pharma-aveo?utm_source=advfn.com&utm_medium=referral
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more AVEO Pharmaceuticals Charts.
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more AVEO Pharmaceuticals Charts.